In this study, we evaluated the efficacy of anti-HER2 therapy to sensitize HER2+ breast cancer to fractionated radiation at both the cellular and molecular level with in vitro and in vivo cell-line models and PDX models of HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.